216 related articles for article (PubMed ID: 18268490)
1. The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer.
McKernan M; McMillan DC; Anderson JR; Angerson WJ; Stuart RC
Br J Cancer; 2008 Mar; 98(5):888-93. PubMed ID: 18268490
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study.
van Kleef JJ; Dijksterhuis WPM; van den Boorn HG; Prins M; Verhoeven RHA; Gisbertz SS; Slingerland M; Mohammad NH; Creemers GJ; Neelis KJ; Heisterkamp J; Rosman C; Ruurda JP; Kouwenhoven EA; van de Poll-Franse LV; van Oijen MGH; Sprangers MAG; van Laarhoven HWM;
Gastric Cancer; 2021 Nov; 24(6):1203-1212. PubMed ID: 34251543
[TBL] [Abstract][Full Text] [Related]
3. Validation of the polish version of the eortc QLQ-C30 and the QLQ-OG25 for the assessment of health-related quality of life in patients with esophagi-gastric cancer.
Tomaszewski KA; Püsküllüoğlu M; Biesiada K; Bochenek J; Nieckula J; Krzemieniecki K
J Psychosoc Oncol; 2013; 31(2):191-203. PubMed ID: 23514254
[TBL] [Abstract][Full Text] [Related]
4. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach.
Lagergren P; Fayers P; Conroy T; Stein HJ; Sezer O; Hardwick R; Hammerlid E; Bottomley A; Van Cutsem E; Blazeby JM;
Eur J Cancer; 2007 Sep; 43(14):2066-73. PubMed ID: 17702567
[TBL] [Abstract][Full Text] [Related]
5. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
6. Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients.
Grande GE; Farquhar MC; Barclay SI; Todd CJ
Palliat Support Care; 2009 Sep; 7(3):289-97. PubMed ID: 19788770
[TBL] [Abstract][Full Text] [Related]
7. Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation.
Bergquist H; Johnsson A; Hammerlid E; Wenger U; Lundell L; Ruth M
Aliment Pharmacol Ther; 2008 Mar; 27(5):385-95. PubMed ID: 18081735
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors of overall well-being using the EORTC QLQ-C15-PAL extracted from the EORTC QLQ-C30.
Lam K; Zeng L; Zhang L; Tseng LM; Hou MF; Fairchild A; Vassiliou V; Jesus-Garcia R; Alm El-Din MA; Kumar A; Forges F; Chie WC; Sahgal A; Poon M; Chow E
J Palliat Med; 2013 Apr; 16(4):402-8. PubMed ID: 23458649
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life and treatment modality among esophageal squamous cell carcinoma survivors: A prospective study using time to deterioration model analysis.
Liu S; Lin Z; Lin J; Chen H; Xie Q; Rao W; Chen Y; Yu K; Hu Z
J Surg Oncol; 2021 Jan; 123(1):156-163. PubMed ID: 33126290
[TBL] [Abstract][Full Text] [Related]
10. Psychometric analysis of a Persian version of the European Organization for Research and Treatment of Cancer OG25 Quality of Life Questionnaire in oesophagogastric cancer patients.
Hesari AE; Lari MA; Shandiz FH
Asian Pac J Cancer Prev; 2014; 15(6):2739-45. PubMed ID: 24761894
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
12. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites.
Quinten C; Martinelli F; Coens C; Sprangers MA; Ringash J; Gotay C; Bjordal K; Greimel E; Reeve BB; Maringwa J; Ediebah DE; Zikos E; King MT; Osoba D; Taphoorn MJ; Flechtner H; Schmucker-Von Koch J; Weis J; Bottomley A;
Cancer; 2014 Jan; 120(2):302-11. PubMed ID: 24127333
[TBL] [Abstract][Full Text] [Related]
13. Validation and comparison of the health-related quality-of-life instruments EORTC QLQ-C30 and SF-36 in assessment of patients with chronic nonmalignant pain.
Fredheim OM; Borchgrevink PC; Saltnes T; Kaasa S
J Pain Symptom Manage; 2007 Dec; 34(6):657-65. PubMed ID: 17618079
[TBL] [Abstract][Full Text] [Related]
14. EORTC QLQ-C15-PAL quality of life score as a prognostic indicator of survival in patients with far advanced cancer.
Lee YJ; Suh SY; Choi YS; Shim JY; Seo AR; Choi SE; Ahn HY; Yim E
Support Care Cancer; 2014 Jul; 22(7):1941-8. PubMed ID: 24577883
[TBL] [Abstract][Full Text] [Related]
15. The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30.
Guzelant A; Goksel T; Ozkok S; Tasbakan S; Aysan T; Bottomley A
Eur J Cancer Care (Engl); 2004 May; 13(2):135-44. PubMed ID: 15115469
[TBL] [Abstract][Full Text] [Related]
16. Content validation of the EORTC QLQ-C15-PAL with advanced cancer patients and health care professionals from palliative care services in Chile.
Rojas-Concha L; Hansen MB; Petersen MA; Groenvold M
BMC Palliat Care; 2020 Jun; 19(1):81. PubMed ID: 32517678
[TBL] [Abstract][Full Text] [Related]
17. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values.
Mercieca-Bebber R; Costa DS; Norman R; Janda M; Smith DP; Grimison P; Gamper EM; King MT
Med J Aust; 2019 Jun; 210(11):499-506. PubMed ID: 31155722
[TBL] [Abstract][Full Text] [Related]
18. Quality of life after palliative treatment for oesophageal carcinoma -- a prospective comparison between stent placement and single dose brachytherapy.
Homs MY; Essink-Bot ML; Borsboom GJ; Steyerberg EW; Siersema PD;
Eur J Cancer; 2004 Aug; 40(12):1862-71. PubMed ID: 15288288
[TBL] [Abstract][Full Text] [Related]
19. Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients.
Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AK; Tang NL; Chu CM; Hui J; Lee KF; Yu S; Yeo W
Qual Life Res; 2019 Sep; 28(9):2597-2607. PubMed ID: 31037590
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
Bascoul-Mollevi C; Gourgou S; Galais MP; Raoul JL; Bouché O; Douillard JY; Adenis A; Etienne PL; Juzyna B; Bedenne L; Conroy T
Eur J Cancer; 2017 Oct; 84():239-249. PubMed ID: 28829992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
